CO6950482A2 - Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización - Google Patents

Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización

Info

Publication number: CO6950482A2
Authority: CO; Colombia
Prior art keywords: compositions; treatment; methods; rheumatoid arthritis; rheumatoid
Prior art date: 2011-10-11

Application number

CO14099490A

Other languages

English (en)

Inventor

Xiaohong Huang

Martine Jasson

Vanessa Marks

Allen Radin

Original Assignee

Sanofi Sa

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-11

Filing date

2014-05-09

Publication date

2014-05-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48081395&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6950482(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-09 Application filed by Sanofi Sa, Regeneron Pharma filed Critical Sanofi Sa

2014-05-20 Publication of CO6950482A2 publication Critical patent/CO6950482A2/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C19/00—Alloys based on nickel or cobalt
- C22C19/03—Alloys based on nickel or cobalt based on nickel
- C22C19/05—Alloys based on nickel or cobalt based on nickel with chromium
- C22C19/058—Alloys based on nickel or cobalt based on nickel with chromium without Mo and W
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B—PERFORMING OPERATIONS; TRANSPORTING
- B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
- B21D—WORKING OR PROCESSING OF SHEET METAL OR METAL TUBES, RODS OR PROFILES WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
- B21D22/00—Shaping without cutting, by stamping, spinning, or deep-drawing
- B21D22/02—Stamping using rigid devices or tools
- B21D22/022—Stamping using rigid devices or tools by heating the blank or stamping associated with heat treatment
- B—PERFORMING OPERATIONS; TRANSPORTING
- B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
- B21J—FORGING; HAMMERING; PRESSING METAL; RIVETING; FORGE FURNACES
- B21J1/00—Preparing metal stock or similar ancillary operations prior, during or post forging, e.g. heating or cooling
- B21J1/06—Heating or cooling methods or arrangements specially adapted for performing forging or pressing operations
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C19/00—Alloys based on nickel or cobalt
- C22C19/03—Alloys based on nickel or cobalt based on nickel
- C22C19/05—Alloys based on nickel or cobalt based on nickel with chromium
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
- C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
- C22F1/10—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

CO14099490A 2011-10-11 2014-05-09 Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización CO6950482A2 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161545864P	2011-10-11	2011-10-11
EP12305889		2012-07-20

Publications (1)

Publication Number	Publication Date
CO6950482A2 true CO6950482A2 (es)	2014-05-20

Family

ID=48081395

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CO14099490A CO6950482A2 (es)	2011-10-11	2014-05-09	Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización

Country Status (30)

Country	Link
US (2)	US10927435B2 (es)
EP (1)	EP2766039B1 (es)
JP (4)	JP6122018B2 (es)
KR (3)	KR20220035272A (es)
CN (2)	CN108310376A (es)
AR (1)	AR088289A1 (es)
AU (1)	AU2012323062B2 (es)
BR (1)	BR112014008764A8 (es)
CA (1)	CA2851751A1 (es)
CL (1)	CL2014000926A1 (es)
CO (1)	CO6950482A2 (es)
DK (1)	DK2766039T3 (es)
ES (1)	ES2660112T3 (es)
HU (1)	HUE036561T2 (es)
IL (1)	IL232001A0 (es)
LT (1)	LT2766039T (es)
MA (1)	MA35620B1 (es)
MX (2)	MX353126B (es)
MY (1)	MY177212A (es)
NO (1)	NO2766039T3 (es)
PL (1)	PL2766039T3 (es)
PT (1)	PT2766039T (es)
RS (1)	RS56973B1 (es)
RU (1)	RU2664697C2 (es)
SG (3)	SG10201607215SA (es)
SI (1)	SI2766039T1 (es)
TR (1)	TR201802387T4 (es)
TW (1)	TWI589299B (es)
UY (1)	UY34387A (es)
WO (1)	WO2013053751A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR087305A1 (es)	2011-07-28	2014-03-12	Regeneron Pharma	Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) *	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en)	2011-10-11	2018-04-17	Sanofi Biotechnology	Methods for the treatment of rheumatoid arthritis
WO2014096464A1 (de) *	2013-01-31	2014-06-26	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Pharmazeutische zusammensetzung umfassend leflunomid
BR112016009460B1 (pt) *	2013-10-31	2020-09-29	Regeneron Pharmaceuticals, Inc.	Método para detectar a presença de anticorpos neutralizantes
SG10201804000TA (en) *	2013-11-22	2018-07-30	Sanofi Biotechnology	Compositions for the treatment of rheumatoid arthritis and methods of using same
ES2799439T3 (es) *	2013-11-22	2020-12-17	Sanofi Biotechnology	Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas
ES2894259T3 (es) *	2014-09-16	2022-02-14	Sanofi Biotechnology	Composiciones para mejorar la calidad de vida relacionada con la salud de pacientes con artritis reumatoide
JP2018523684A (ja)	2015-08-18	2018-08-23	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EP3371224A1 (en) *	2015-11-03	2018-09-12	Sanofi Biotechnology	Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
KR101895950B1 (ko) *	2015-12-18	2018-09-06	(주)한국비엠아이	골관절염 치료를 위한 친수화된 설파살라진 및 히알루론산을 포함하는 조성물 및 이의제조방법
TN2018000312A1 (en) *	2016-03-07	2020-01-16	Regeneron Pharma	Compositions and methods for treating rheumatoid arthritis
EP3216461A1 (en) *	2016-03-07	2017-09-13	Sanofi Biotechnology	Compositions and methods for treating rheumatoid arthritis
CN107456455B (zh) *	2016-06-06	2021-09-24	海南先声药业有限公司	一种预防或治疗炎性疾病的药物组合物
US11020686B2 (en)	2016-08-16	2021-06-01	Regeneron Pharmaceuticals, Inc.	Methods for quantitating individual antibodies from a mixture
CN109923411B (zh)	2016-10-25	2022-05-31	里珍纳龙药品有限公司	用于色谱数据分析的方法和***
MX2020005699A (es) *	2017-12-13	2020-10-16	Regeneron Pharma	Dispositivos y sistemas para manipulacion de soportes de lecho de columna para cromatografia y metodos relacionados.
WO2019136211A1 (en) *	2018-01-05	2019-07-11	Attillaps Holdings	Treating autoimmune disorders with ivermectin
CN108597083A (zh) *	2018-04-28	2018-09-28	江苏食品药品职业技术学院	一种酒店旅游自助服务***
TWI814812B (zh)	2018-05-02	2023-09-11	美商里珍納龍藥品有限公司	用於評估生化過濾器的適合性的方法
CA3104470A1 (en) *	2018-06-19	2019-12-26	Regeneron Pharmaceuticals, Inc.	Anti-factor xii/xiia antibodies and uses thereof
TW202005694A (zh)	2018-07-02	2020-02-01	美商里珍納龍藥品有限公司	自混合物製備多肽之系統及方法
CN109013990A (zh) *	2018-08-04	2018-12-18	安徽盛美金属科技有限公司	一种加热铝合金锻压件坯料的装置
MA53481A (fr)	2018-08-29	2021-07-07	Regeneron Pharma	Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde
CN109858649A (zh) *	2019-01-04	2019-06-07	珠海格力电器股份有限公司	预订酒店方法和装置、酒店管理方法和装置
EP3917618A1 (en)	2019-01-31	2021-12-08	Sanofi Biotechnology	Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
KR102453140B1 (ko)	2021-09-07	2022-10-11	배호진	블록체인을 이용한 후원자 보상 방법 및 장치

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0747045B2 (ja)	1986-10-15	1995-05-24	株式会社大協精工	積層した注射器用滑栓
US5670373A (en)	1988-01-22	1997-09-23	Kishimoto; Tadamitsu	Antibody to human interleukin-6 receptor
US5171840A (en)	1988-01-22	1992-12-15	Tadamitsu Kishimoto	Receptor protein for human B cell stimulatory factor-2
US5216128A (en)	1989-06-01	1993-06-01	Yeda Research And Development Co., Ltd.	IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
ATE144713T1 (de)	1989-07-20	1996-11-15	Tadamitsu Kishimoto	Antikörper gegen menschlichen interleukin-6- rezeptor
US5605690A (en)	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5016784A (en)	1990-02-15	1991-05-21	Dexus Research Inc.	Applicator for highly reactive materials
ES2289997T3 (es)	1991-03-18	2008-02-16	New York University	Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
WO1992019759A1 (en)	1991-04-25	1992-11-12	Chugai Seiyaku Kabushiki Kaisha	Reconstituted human antibody against human interleukin 6 receptor
JP3100727B2 (ja)	1992-01-23	2000-10-23	株式会社大協精工	変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr)	1992-08-13	1994-10-21	Innotherapie Lab Sa	Anticorps monoclonaux anti-IL6R, et leurs applications.
WO1994006476A1 (en)	1992-09-15	1994-03-31	Immunex Corporation	Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0672144A1 (en)	1992-10-20	1995-09-20	Chiron Corporation	Interleukin-6 receptor antagonists
US5888511A (en)	1993-02-26	1999-03-30	Advanced Biotherapy Concepts, Inc.	Treatment of autoimmune diseases, including AIDS
US5888510A (en)	1993-07-21	1999-03-30	Chugai Seiyaku Kabushiki Kaisha	Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en)	1993-10-06	1995-05-01	Board Of Regents, The University Of Texas System	A monoclonal anti-human il-6 receptor antibody
AU700819B2 (en)	1994-10-07	1999-01-14	Chugai Seiyaku Kabushiki Kaisha	Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
CN101829325A (zh)	1994-10-21	2010-09-15	岸本忠三	Il-6受体的抗体在制备药物组合物中的用途
EP0800829B2 (en)	1994-12-29	2012-07-25	Chugai Seiyaku Kabushiki Kaisha	Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
CA2211578C (en)	1995-02-13	2010-09-21	Chugai Seiyaku Kabushiki Kaisha	Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
JP3172057B2 (ja)	1995-04-05	2001-06-04	株式会社大協精工	ラミネートゴム栓
PT923941E (pt)	1996-06-27	2006-09-29	Chugai Pharmaceutical Co Ltd	Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
US7312196B2 (en)	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US20020187150A1 (en)	1997-08-15	2002-12-12	Chugai Seiyaku Kabushiki Kaisha	Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
KR20080027967A (ko)	1997-08-15	2008-03-28	츄가이 세이야꾸 가부시키가이샤	항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
DK1074268T3 (da)	1998-03-17	2008-04-28	Chugai Pharmaceutical Co Ltd	IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
JP4711507B2 (ja)	1998-08-24	2011-06-29	中外製薬株式会社	Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
JP3512349B2 (ja)	1999-01-29	2004-03-29	株式会社大協精工	柱状ゴム要素の成形型
US6670373B1 (en)	1999-10-07	2003-12-30	Eli Lilly And Company	Compounds and method for inhibiting MRP1
US6629949B1 (en)	2000-05-08	2003-10-07	Sterling Medivations, Inc.	Micro infusion drug delivery device
US6659982B2 (en)	2000-05-08	2003-12-09	Sterling Medivations, Inc.	Micro infusion drug delivery device
EP1314437B1 (en)	2000-08-11	2014-06-25	Chugai Seiyaku Kabushiki Kaisha	Stabilized antibody-containing preparations
US7148197B2 (en)	2000-08-24	2006-12-12	The Regents Of The University Of California	Orally administered small peptides synergize statin activity
CA2424371A1 (en)	2000-10-20	2003-04-01	Chugai Seiyaku Kabushiki Kaisha	Agonistic monoclonal antibody fragments
JP4776145B2 (ja)	2000-10-25	2011-09-21	中外製薬株式会社	Ｉｌ−６アンタゴニストを有効成分として含有する乾癬の予防又は治療剤
JP4889187B2 (ja)	2000-10-27	2012-03-07	中外製薬株式会社	Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
JP2002209975A (ja)	2001-01-19	2002-07-30	Daikyo Seiko Ltd	医薬バイアル用ラミネートゴム栓
UA80091C2 (en)	2001-04-02	2007-08-27	Chugai Pharmaceutical Co Ltd	Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20030113316A1 (en)	2001-07-25	2003-06-19	Kaisheva Elizabet A.	Stable lyophilized pharmaceutical formulation of IgG antibodies
EP1562968B1 (en)	2001-11-14	2013-08-21	Janssen Biotech, Inc.	Anti-il-6 antibodies, compositions, methods and uses
ES2536709T3 (es)	2002-02-14	2015-05-27	Chugai Seiyaku Kabushiki Kaisha	Utilización de ácido acético para eliminar los problemas inducidos por el ión Fe en las formulaciones de anticuerpos anti-HM1.24 o anti-IL6R
US20060078533A1 (en)	2004-10-12	2006-04-13	Omoigui Osemwota S	Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078532A1 (en)	2004-10-12	2006-04-13	Omoigui Osemwota S	Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en)	2002-08-22	2006-12-07	Omoigui Osemwota S	Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078531A1 (en)	2004-10-12	2006-04-13	Osemwota Sota	Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US7534427B2 (en)	2002-12-31	2009-05-19	Immunomedics, Inc.	Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
ES2349779T5 (es)	2003-04-04	2013-11-26	Genentech, Inc.	Formulaciones de anticuerpos y de proteínas a concentración elevada
UA99933C2 (ru)	2003-04-09	2012-10-25	Дженентек, Инк.	Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
GB2401040A (en)	2003-04-28	2004-11-03	Chugai Pharmaceutical Co Ltd	Method for treating interleukin-6 related diseases
EP1673396A1 (en)	2003-09-22	2006-06-28	BioVation GmbH & Co.KG.	Use of antibodies for reducing the biological effectiveness of il-6
DE10355251A1 (de)	2003-11-26	2005-06-23	Merck Patent Gmbh	Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en)	2003-12-19	2013-12-31	Chugai Seiyaku Kabushiki Kaisha	Treatment of vasculitis with IL-6 antagonist
ES2341461T5 (es)	2004-02-11	2014-10-29	Warner-Lambert Company Llc	Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6
KR20070047327A (ko)	2004-07-26	2007-05-04	비오겐 아이덱 엠에이 아이엔씨.	항-ｃｄ154 항체
US20070036788A1 (en)	2004-09-22	2007-02-15	Ahmed Sheriff	Use of a compound for reducing the biological effectiveness of il-6
EP1810980A1 (en)	2004-10-28	2007-07-25	Osaka University	Interleukin-6 inhibitors
RU2007126985A (ru)	2004-12-16	2009-01-27	Дженентек, Инк. (Us)	Способы лечения аутоиммунных заболеваний
KR20080071192A (ko)	2005-11-22	2008-08-01	와이어쓰	면역글로불린 융합 단백질 제형
EA014298B1 (ru)	2005-12-13	2010-10-29	Эли Лилли Энд Компани	Анти-il-17-антитела
US20080131374A1 (en)	2006-04-19	2008-06-05	Medich John R	Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) *	2006-06-02	2011-12-20	Regeneron Pharmaceuticals, Inc.	Method of treating rheumatoid arthritis with an IL-6R antibody
ATE537190T1 (de)	2006-06-02	2011-12-15	Regeneron Pharma	Hochaffine antikörper gegen den humanen il-6- rezeptor
BRPI0713421A2 (pt)	2006-06-14	2012-03-13	Imclone Systems Incorporated	Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
US8629244B2 (en)	2006-08-18	2014-01-14	Ablynx N.V.	Interleukin-6 receptor binding polypeptides
US20100129354A1 (en)	2006-10-27	2010-05-27	Ablynx N.V.	Intranasal delivery of polypeptides and proteins
JP2008189637A (ja)	2007-02-08	2008-08-21	Snow Brand Milk Prod Co Ltd	自己免疫疾患予防剤
US20100267934A1 (en)	2007-05-31	2010-10-21	Genmab A/S	Stable igg4 antibodies
BRPI0817250A2 (pt)	2007-09-26	2014-06-17	Chugai Pharmaceutical Co Ltd	Anticorpo anti-receptor da il-6.
WO2009095489A2 (en)	2008-02-01	2009-08-06	Ablynx N.V.	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en)	2008-03-07	2009-09-11	Ferring International Center S. A.	ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
NZ602884A (en)	2008-04-11	2014-08-29	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
RU2565809C2 (ru)	2009-03-19	2015-10-20	Чугаи Сейяку Кабусики Кайся	Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US20130053751A1 (en)	2011-08-31	2013-02-28	Frank Holtham	Needle with an antiseptic swab
TWI589299B (zh) *	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en)	2011-10-11	2018-04-17	Sanofi Biotechnology	Methods for the treatment of rheumatoid arthritis
US20150077582A1 (en)	2013-09-13	2015-03-19	Texas Instruments Incorporated	Method and system for adapting a device for enhancement of images
SG10201804000TA (en)	2013-11-22	2018-07-30	Sanofi Biotechnology	Compositions for the treatment of rheumatoid arthritis and methods of using same

2012
- 2012-10-09 TW TW101137198A patent/TWI589299B/zh active
- 2012-10-10 MX MX2014004398A patent/MX353126B/es active IP Right Grant
- 2012-10-10 WO PCT/EP2012/070052 patent/WO2013053751A1/en active Application Filing
- 2012-10-10 SG SG10201607215SA patent/SG10201607215SA/en unknown
- 2012-10-10 BR BR112014008764A patent/BR112014008764A8/pt not_active Application Discontinuation
- 2012-10-10 LT LTEP12769684.7T patent/LT2766039T/lt unknown
- 2012-10-10 JP JP2014535044A patent/JP6122018B2/ja active Active
- 2012-10-10 NO NO12769684A patent/NO2766039T3/no unknown
- 2012-10-10 AR ARP120103770A patent/AR088289A1/es unknown
- 2012-10-10 EP EP12769684.7A patent/EP2766039B1/en active Active
- 2012-10-10 AU AU2012323062A patent/AU2012323062B2/en active Active
- 2012-10-10 CN CN201810179358.3A patent/CN108310376A/zh active Pending
- 2012-10-10 CA CA2851751A patent/CA2851751A1/en active Pending
- 2012-10-10 PT PT127696847T patent/PT2766039T/pt unknown
- 2012-10-10 KR KR1020227007526A patent/KR20220035272A/ko not_active Application Discontinuation
- 2012-10-10 PL PL12769684T patent/PL2766039T3/pl unknown
- 2012-10-10 HU HUE12769684A patent/HUE036561T2/hu unknown
- 2012-10-10 CN CN201280060133.7A patent/CN104105505A/zh active Pending
- 2012-10-10 TR TR2018/02387T patent/TR201802387T4/tr unknown
- 2012-10-10 SG SG11201401373RA patent/SG11201401373RA/en unknown
- 2012-10-10 KR KR1020197002611A patent/KR20190014117A/ko active Application Filing
- 2012-10-10 MY MYPI2014001045A patent/MY177212A/en unknown
- 2012-10-10 SG SG10201807042YA patent/SG10201807042YA/en unknown
- 2012-10-10 ES ES12769684.7T patent/ES2660112T3/es active Active
- 2012-10-10 KR KR1020147012534A patent/KR20140123474A/ko not_active Application Discontinuation
- 2012-10-10 US US14/350,973 patent/US10927435B2/en active Active
- 2012-10-10 DK DK12769684.7T patent/DK2766039T3/en active
- 2012-10-10 RS RS20180191A patent/RS56973B1/sr unknown
- 2012-10-10 RU RU2014118741A patent/RU2664697C2/ru active
- 2012-10-10 SI SI201231228T patent/SI2766039T1/en unknown
- 2012-10-11 UY UY0001034387A patent/UY34387A/es not_active Application Discontinuation
2014
- 2014-04-08 IL IL232001A patent/IL232001A0/en active IP Right Grant
- 2014-04-10 MX MX2021015309A patent/MX2021015309A/es unknown
- 2014-04-11 CL CL2014000926A patent/CL2014000926A1/es unknown
- 2014-05-01 MA MA36969A patent/MA35620B1/fr unknown
- 2014-05-09 CO CO14099490A patent/CO6950482A2/es unknown
2017
- 2017-03-29 JP JP2017064130A patent/JP6336171B2/ja active Active
2018
- 2018-04-27 JP JP2018086193A patent/JP6983717B2/ja active Active
2020
- 2020-05-21 JP JP2020088567A patent/JP7025477B2/ja active Active
- 2020-12-24 US US17/133,870 patent/US20210230719A1/en active Pending

Also Published As

Publication number	Publication date
AR088289A1 (es)	2014-05-21
TR201802387T4 (tr)	2018-03-21
US20140302053A1 (en)	2014-10-09
JP2020143121A (ja)	2020-09-10
SG11201401373RA (en)	2014-05-29
PT2766039T (pt)	2018-02-26
US10927435B2 (en)	2021-02-23
JP2017137338A (ja)	2017-08-10
HUE036561T2 (hu)	2018-07-30
WO2013053751A1 (en)	2013-04-18
CN104105505A (zh)	2014-10-15
DK2766039T3 (en)	2018-03-05
KR20190014117A (ko)	2019-02-11
NO2766039T3 (es)	2018-04-21
CL2014000926A1 (es)	2014-11-21
EP2766039A1 (en)	2014-08-20
SG10201607215SA (en)	2016-10-28
JP6122018B2 (ja)	2017-04-26
SG10201807042YA (en)	2018-09-27
AU2012323062A1 (en)	2014-05-01
JP6983717B2 (ja)	2021-12-17
EP2766039B1 (en)	2017-11-22
MA35620B1 (fr)	2014-11-01
RU2014118741A (ru)	2015-11-20
US20210230719A1 (en)	2021-07-29
RU2664697C2 (ru)	2018-08-21
TWI589299B (zh)	2017-07-01
BR112014008764A2 (pt)	2017-06-13
RS56973B1 (sr)	2018-05-31
CN108310376A (zh)	2018-07-24
MY177212A (en)	2020-09-09
KR20220035272A (ko)	2022-03-21
SI2766039T1 (en)	2018-05-31
MX2021015309A (es)	2022-06-02
BR112014008764A8 (pt)	2017-10-31
AU2012323062B2 (en)	2017-08-31
UY34387A (es)	2013-05-31
JP2018135373A (ja)	2018-08-30
TW201321017A (zh)	2013-06-01
KR20140123474A (ko)	2014-10-22
MX2014004398A (es)	2014-09-08
LT2766039T (lt)	2018-04-10
JP7025477B2 (ja)	2022-02-24
ES2660112T3 (es)	2018-03-20
CA2851751A1 (en)	2013-04-18
MX353126B (es)	2017-12-20
PL2766039T3 (pl)	2018-06-29
IL232001A0 (en)	2014-05-28
JP6336171B2 (ja)	2018-06-06
JP2014530226A (ja)	2014-11-17

Publication	Publication Date	Title
CO6950482A2 (es)	2014-05-20	Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización
CO6801724A2 (es)	2013-11-29	Composiciones y métodos para el tratamiento de la mielofibrosis
ES2966588T3 (es)	2024-04-23	Aparato y procedimiento para descentralizar el procesamiento de un objeto
CO6791602A2 (es)	2013-11-14	Métodos y sistemas para el tratamiento de pozos
CO6930366A2 (es)	2014-04-28	Método para el tratamiento de vhc
CO6900118A2 (es)	2014-03-20	Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
BR112013024401A2 (pt)	2017-11-07	métodos e composições para o tratamento do transtorno do déficit de atenção
CO6811858A2 (es)	2013-12-16	Nuevos derivados de imidazol útiles para el tratamiento de artritis
BR112014004569A2 (pt)	2017-06-13	composto da fórmula i, métodos para tratar condição inflamatória, artrite reumatoide, asma e distúrbio imune, composição farmacêutica e uso do composto
BR112013019732A2 (pt)	2016-10-25	composições e métodos para tratamento de doenças cardiovasculares
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
DK2854769T3 (da)	2023-06-26	Fremgangsmåder til behandling af artritis
CO6821964A2 (es)	2013-12-31	Compuestos para el tratamiento de la adicción
ES2579990T8 (es)	2016-08-26	Métodos y composiciones para tratar el síndrome metabólico
DK2563385T3 (da)	2017-11-06	Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis
CO6801718A2 (es)	2013-11-29	Composición terapéutica para el tratamiento de glioblastoma
CO6821965A2 (es)	2013-12-31	1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112014004416A2 (pt)	2017-03-28	composições e métodos para o tratamento de doenças neurodegenerativas
BR112013028890A2 (pt)	2017-01-31	composições e métodos para o tratamento de câncer
BR112013015048A2 (pt)	2016-07-19	composição para o tratamento de distúrbios metabólicos
BR112013018453A2 (pt)	2018-05-22	métodos e composições para a prevenção e tratamento de osteoartrite
CO6880061A2 (es)	2014-02-28	Método para tratar el cáncer mediante el uso combinado de fármacos
BR112014011898A2 (pt)	2017-05-16	métodos e composições para o tratamento de diabetes e sintomas relacionados
BR112013012764A2 (pt)	2016-09-13	método para produzir uma olefina
BR112013020025A2 (pt)	2017-03-21	derivados de aminoestatina para o tratamento de artrose